Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
用户sar7Gc5emZOY
2小时前
14
10
已关闭
DOI: 10.1016/s2213-2600(26)00142-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213260026001426
其他信息:
出版社: Elsevier BV
作者: Zhengbo Song; Xingya Li; Rongbo Lin; Huaqiu Shi; Yuan Yuan; Ying Liu; Yongzhong Luo; Tangfeng Lv; Yiping Zhang; Liming Zhu; Yinxin Zhu; Ling Zhang; Zaiqi Wang

